Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
XHSvsXBIETF Comparison
SPDR S&P Health Care Services ETF (XHS) and SPDR S&P Biotech ETF (XBI) belong to the same industry segment: US Health Care. Both ETFs have the same top 3 sector exposures: and Health Care. Both XHS and XBI have the same Total Expense Ratio (TER) of 0.35%. XHS is down -1.55% year-to-date (YTD) with +$6M in YTD flows. XBI performs better with 4.5% YTD performance, and -$163M in YTD flows. Run a side-by-side ETF comparison of XHS and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
XHS vs XBI performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | XHS XBI | -0.71%+1.75% | -2.04%+4.75% | -1.55%+4.50% | +11.15%+48.40% | +26.55%+69.29% | +1.67%-9.32% |
| Flows | XHS XBI | -$8M-$21M | +$2M-$262M | +$6M-$163M | -$3M-$25M | -$36M-$1.83B | -$38M+$1.19B |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | XHS XBI | +17.76%+25.66% | +19.20%+28.03% | +18.15%+27.31% | +21.13%+32.96% |
| Max drawdown | XHS XBI | -5.98%-8.19% | -12.54%-21.44% | -17.78%-32.94% | -32.53%-57.63% |
| Max drawdown duration | XHS XBI | 63d47d | 128d141d | 362d331d | 1716d1821d |
XHS | XBI | |
Last sale 3/11/2026 at 1:30 PM | $104.90 | $126.38 |
| Previous close 03/10/2026 | $105.14 | $127.43 |
| Consolidated volume 03/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
XHS | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
XHS | XBI | |
|---|---|---|
| Last price | $104.90 | $126.38 |
| 1D performance | -0.23% | -0.82% |
| AuM | $87.35 M | $8.06 B |
| E/R | 0.35% | 0.35% |
XHS | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | SPDR | SPDR |
| Benchmark | S&P Health Care Services Select Industry Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 52 | 123 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | September 28, 2011 | January 31, 2006 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the XHS and XBI ETFs performed in 2026?
As of March 10, 2026, XHS is down -1.55% year-to-date (YTD), while XBI has returned 4.5%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: XHS or XBI?
Year-to-date, the XHS ETF saw +$6M in flows, compared to -$163M for XBI.
Which ETF is more volatile: XHS or XBI?
Over the past year, XHS had a volatility of 19.2%, while XBI experienced 28.03%.
Which ETF is bigger: XHS or XBI?
As of March 10, 2026, XHS holds $87.35 M in assets under management (AUM), while XBI manages $8.06 B.
What sectors do the XHS and XBI ETFs invest in?
XHS leans toward sectors like Health Care. Meanwhile, XBI focuses on Health Care.
What are the top holdings of the XHS ETF and XBI ETF?
XHS top holdings include BROOKDALE SENIOR LIVING, ALIGNMENT HEALTHCARE and US20603L1026. XBI holds in its top three: MODERNA INC, MIRUM PHARMACEUTICALS INC and REVOLUTION MEDICINES INC.
Which ETF is more diversified: XHS or XBI?
XHS holds 59 securities with 33.22% of its assets in the top 15. XBI has 149 securities and a top 15 weight of 21.6%.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Are Biotechnology ETFs In the Midst of a Comeback?
Two biotech ETFs to watch for the rest of 2022 and beyond
Biotech ETFs – Investing in Health Innovation
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
